Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Veritas In Silico Inc. has partnered with Liverpool ChiroChem to develop mRNA-targeted small molecule drugs, aiming to create innovative therapeutics for various diseases. This strategic collaboration combines both companies' platforms to potentially generate groundbreaking drug candidates. The agreement marks a significant step in Veritas In Silico's growth strategy, although no immediate revenue is expected from this contract.
For further insights into JP:130A stock, check out TipRanks' Stock Analysis page.